SCHEMBL6064531

SCHEMBL6064531

O=C(O)c1cccc(S(=O)(=O)O)c1OS(=O)(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
ALDH1A1 P00352 3/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
F2 P00734 3/20 0.39
PRSS1 P07477 3/20 0.39
PRSS2 P07478 3/20 0.39
PRSS3 P35030 3/20 0.39
CA12 O43570 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrazine SCHEMBL9314976 0.97 F2 (0.41) ALOX15CA1CA2MMP1MMP2
Ethylenediamine SCHEMBL10684380 0.92 CYP1A2 (0.39) ALOX15CA1CA2MMP1MMP2
SCHEMBL9766397 0.87 ALDH1A1 (0.46) ALOX15CA1CA2MMP1MMP2
SCHEMBL7284889 0.83 F2 (0.48) ALOX15CA1CA2MMP1MMP2
SCHEMBL28861367 0.79 ALDH1A1 (0.40) ALOX15CA1CA2MMP1MMP2
SCHEMBL11651045 0.79 MMP2 (0.50) ALOX15MMP2ALDH1A1HSD17B10TSHR
SCHEMBL28244595 0.79 PRNP (0.42) ALOX15CA1CA2MMP1MMP2
SCHEMBL28057527 0.79 ALB (0.50) ALOX15ALDH1A1HSD17B10MAPK1KDM4E
SCHEMBL29032363 0.77 MAPK1 (0.45) ALOX15CA1CA2MMP1MMP2
SCHEMBL1308246 0.77 ALDH1A1 (0.38) ALOX15CA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102523-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF JUBILANT DRAXIMAGE INC (CA) 2026-04-16 US claimed
US-12440583-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof JUBILANT DRAXIMAGE, INC. (CA) 2025-10-14 US claimed
EP-3592735-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF TETROFOSMIN OR ACID ADDITION SALT THEREOF JUBILANT GENERICS LTD FORMERLY A DIVISION OF JUBILANT LIFE SCIENCES LTD (IN) 2024-03-20 EP claimed
US-20240050598-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF JUBILANT DRAXIMAGE INC. (CA) 2024-02-15 US claimed
US-11857647-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof JUBILANT DRAXIMAGE, INC. 2024-01-02 US claimed
CN-116059409-A Novel technetium-99 m therapeutic diagnostic agent for cardiac radiography and ventricular evaluation and evaluation method 程毓渡 2023-05-05 CN claimed
CN-114940553-A Unipolar and bipolar electric control ion exchange reactor and group 中联西北工程设计研究院有限公司 2022-08-26 CN claimed
EP-1085984-B1 I INKJET RECEPTOR MEDIA AND COATING SOLUTIONS THEREFOR MINNESOTA MINING & MFG (US) 2005-12-28 EP claimed
US-6383612-B1 PIGMENT METAL SALT COATING IMPREGNATED INTO POROUS MEMBRANE; AROMATIC OR ALIPHATIC DRYING AGENT WITH SULFONIC, CARBOXYLIC, PHENOLIC, AND/OR HYDROXYL FUNCTIONAL GROUPS; WATERPROOFING, COLORFASTNESS, NONSMEARING 3M INNOVATIVE PROPERTIES COMPANY 2002-05-07 US claimed
EP-1085984-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2001-03-28 EP claimed
WO-1999065702-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-12-23 WO claimed
US-20260102523-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF JUBILANT DRAXIMAGE INC (CA) 2026-04-16 US disclosed
US-12440583-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof JUBILANT DRAXIMAGE, INC. (CA) 2025-10-14 US disclosed
US-20250299889-A1 SOLID ELECTROLYTIC CAPACITOR ELEMENT AND SOLID ELECTROLYTIC CAPACITOR PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2025-09-25 US disclosed
US-20250104928-A1 ELECTROLYTIC CAPACITOR AND METHOD OF MANUFACTURING SAME PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2025-03-27 US disclosed
WO-2003064166-A1 RECEPTOR MEDIUM HAVING A MICROFIBRILLATED SURFACE 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-08-07 WO disclosed
US-6383612-B1 PIGMENT METAL SALT COATING IMPREGNATED INTO POROUS MEMBRANE; AROMATIC OR ALIPHATIC DRYING AGENT WITH SULFONIC, CARBOXYLIC, PHENOLIC, AND/OR HYDROXYL FUNCTIONAL GROUPS; WATERPROOFING, COLORFASTNESS, NONSMEARING 3M INNOVATIVE PROPERTIES COMPANY 2002-05-07 US disclosed
EP-1085984-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2001-03-28 EP disclosed
WO-1999065702-A1 INK-DRYING AGENTS FOR INKJET RECEPTOR MEDIA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-12-23 WO disclosed
US-4331788-A ACTIVATION WITH SOLUBLE METAL COMPLEX AND NITRIC ACID CHLOE CHIMIE (FR) 1982-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11857647-B2 Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof TREH, TYMP, PRCP ALOX15 4873/4885CA1 1233/4885CA2 1719/4885
US-20260102523-A1 PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TREH, CD68, THPO ALOX15 3850/4885CA1 52/4885CA2 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.